JP2022524449A5 - - Google Patents

Info

Publication number
JP2022524449A5
JP2022524449A5 JP2021554761A JP2021554761A JP2022524449A5 JP 2022524449 A5 JP2022524449 A5 JP 2022524449A5 JP 2021554761 A JP2021554761 A JP 2021554761A JP 2021554761 A JP2021554761 A JP 2021554761A JP 2022524449 A5 JP2022524449 A5 JP 2022524449A5
Authority
JP
Japan
Prior art keywords
antibody
seq
antibody fragment
region
isolated antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021554761A
Other languages
English (en)
Japanese (ja)
Other versions
JP7617012B2 (ja
JP2022524449A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/056754 external-priority patent/WO2020182974A1/en
Publication of JP2022524449A publication Critical patent/JP2022524449A/ja
Publication of JP2022524449A5 publication Critical patent/JP2022524449A5/ja
Priority to JP2025001775A priority Critical patent/JP7842914B2/ja
Application granted granted Critical
Publication of JP7617012B2 publication Critical patent/JP7617012B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021554761A 2019-03-14 2020-03-13 Ｃ５ａＲを標的とする抗体 Active JP7617012B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025001775A JP7842914B2 (ja) 2019-03-14 2025-01-06 Ｃ５ａＲを標的とする抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19162759 2019-03-14
EP19162759.5 2019-03-14
PCT/EP2020/056754 WO2020182974A1 (en) 2019-03-14 2020-03-13 Antibodies targeting c5ar

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025001775A Division JP7842914B2 (ja) 2019-03-14 2025-01-06 Ｃ５ａＲを標的とする抗体

Publications (3)

Publication Number Publication Date
JP2022524449A JP2022524449A (ja) 2022-05-02
JP2022524449A5 true JP2022524449A5 (https=) 2023-03-17
JP7617012B2 JP7617012B2 (ja) 2025-01-17

Family

ID=65812165

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021554761A Active JP7617012B2 (ja) 2019-03-14 2020-03-13 Ｃ５ａＲを標的とする抗体
JP2025001775A Active JP7842914B2 (ja) 2019-03-14 2025-01-06 Ｃ５ａＲを標的とする抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025001775A Active JP7842914B2 (ja) 2019-03-14 2025-01-06 Ｃ５ａＲを標的とする抗体

Country Status (14)

Country Link
US (3) US20220135658A1 (https=)
EP (1) EP3938393A1 (https=)
JP (2) JP7617012B2 (https=)
KR (1) KR20210141988A (https=)
CN (1) CN113574072B (https=)
AU (1) AU2020235263A1 (https=)
BR (1) BR112021017860A2 (https=)
CA (1) CA3132771A1 (https=)
IL (1) IL286238A (https=)
MA (1) MA55285A (https=)
MX (1) MX2021011040A (https=)
SG (1) SG11202108761YA (https=)
TW (1) TWI901581B (https=)
WO (1) WO2020182974A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
WO2022057910A1 (en) * 2020-09-17 2022-03-24 I-Mab Biopharma Co., Ltd Combination therapies targeting c5ar and pd-1/pd-l1 pathways
CA3173944A1 (en) 2021-01-13 2022-07-21 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
WO2024236163A1 (en) 2023-05-17 2024-11-21 Morphosys Ag T cell receptor beta constant region 2 (trbc2) antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
US8071096B2 (en) * 2002-01-25 2011-12-06 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
MX2010005603A (es) * 2007-11-26 2010-08-02 Bayer Schering Pharma Ag Anticuerpos antimesotelina y usos de los mismos.
RU2010138612A (ru) 2008-02-20 2012-03-27 Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR
MX340696B (es) * 2010-04-30 2016-07-21 Alexion Pharma Inc Anticuerpos anti-c5a y metodos para usar los anticuerpos.
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
DK3424953T3 (en) * 2011-06-06 2020-11-02 Novo Nordisk As Terapeutiske antistoffer
JP2016523829A (ja) * 2013-05-08 2016-08-12 ノヴォ ノルディスク アー／エス Ｃ５ａｒアンタゴニストの使用
ES2736500T3 (es) 2014-06-18 2020-01-02 Morphosys Ag Proteínas de fusión y usos de las mismas
TWI786132B (zh) 2017-06-23 2022-12-11 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療

Similar Documents

Publication Publication Date Title
JP2022191383A5 (https=)
JP2022524449A5 (https=)
JP7583707B2 (ja) 抗ｃｄ４７抗体及びその応用
JP2024109678A5 (https=)
JP2022116269A5 (https=)
JP2020108386A (ja) Ｃｄ３及びｃｄ３８に結合するヘテロ二量体抗体
JP2021526022A5 (https=)
JP2021524244A5 (https=)
CN115461368A (zh) 抗人白细胞介素-4受体α抗体及其制备方法和应用
RU2014147773A (ru) Человеческие антитела с высокой аффинностью к рецепторам il-4 человека
IL273841B1 (en) Antibodies targeting cd137 and methods of use thereof
JP2020505927A5 (https=)
JP2023093753A5 (https=)
CN111615519B (zh) 结合人il-5的单克隆抗体、其制备方法和用途
JP2023506750A5 (https=)
JP2023545183A5 (https=)
JP2024540148A5 (https=)
JP2023545182A5 (https=)
HRP20191277T1 (hr) Anti-cd26 antitijela i njihove primjene
JP2023510844A5 (https=)
JP2024516098A5 (https=)
JP2026001077A5 (https=)
CN102690789A (zh) 分泌破伤风外毒素单克隆抗体的杂交瘤细胞株及由其制备的单克隆抗体、Fab抗体与应用
JP2024546763A5 (https=)
JP2024546759A5 (https=)